These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 17034443)
21. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation. Ngo HT; Tait RJ; Hulse GK Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134 [TBL] [Abstract][Full Text] [Related]
22. Complaints of heroin-maintained patients: A survey of symptoms ascribed to diacetylmorphine. Dürsteler-MacFarland KM; Stohler R; Moldovanyi A; Rey S; Basdekis R; Gschwend P; Eschmann S; Rehm J Drug Alcohol Depend; 2006 Feb; 81(3):231-9. PubMed ID: 16135401 [TBL] [Abstract][Full Text] [Related]
23. Reductions in heroin use are not associated with increases in other drug use: 2-year findings from the Australian Treatment Outcome Study. Darke S; Williamson A; Ross J; Teesson M Drug Alcohol Depend; 2006 Sep; 84(2):201-5. PubMed ID: 16580792 [TBL] [Abstract][Full Text] [Related]
24. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Binder T; Vavrinková B Neuro Endocrinol Lett; 2008 Feb; 29(1):80-6. PubMed ID: 18283247 [TBL] [Abstract][Full Text] [Related]
25. Epigenetic Effects of Intravenous Diacetylmorphine on the Methylation of POMC and NR3C1. Groh A; Rhein M; Buchholz V; Burkert A; Huber CG; Lang UE; Borgwardt SJ; Heberlein A; Muschler MAN; Hillemacher T; Bleich S; Frieling H; Walter M Neuropsychobiology; 2017; 75(4):193-199. PubMed ID: 29510398 [TBL] [Abstract][Full Text] [Related]
27. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474 [TBL] [Abstract][Full Text] [Related]
28. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Termorshuizen F; Krol A; Prins M; Geskus R; van den Brink W; van Ameijden EJ Drug Alcohol Depend; 2005 Aug; 79(2):231-40. PubMed ID: 16002032 [TBL] [Abstract][Full Text] [Related]
29. Intravenous and intranasal heroin-dependent treatment-seekers: characteristics and treatment outcome. Highfield DA; Schwartz RP; Jaffe JH; O'Grady KE Addiction; 2007 Nov; 102(11):1816-23. PubMed ID: 17784892 [TBL] [Abstract][Full Text] [Related]
30. Rate of methadone use among Aboriginal opioid injection drug users. Wood E; Montaner JS; Li K; Barney L; Tyndall MW; Kerr T CMAJ; 2007 Jul; 177(1):37-40. PubMed ID: 17606937 [TBL] [Abstract][Full Text] [Related]
31. From illegal poison to legal medicine: a qualitative research in a heroin-prescription trial in Spain. Romo N; Poo M; Ballesta R; Drug Alcohol Rev; 2009 Mar; 28(2):186-95. PubMed ID: 19320704 [TBL] [Abstract][Full Text] [Related]
32. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Davoli M; Bargagli AM; Perucci CA; Schifano P; Belleudi V; Hickman M; Salamina G; Diecidue R; Vigna-Taglianti F; Faggiano F; Addiction; 2007 Dec; 102(12):1954-9. PubMed ID: 18031430 [TBL] [Abstract][Full Text] [Related]
33. Arterial and venous pharmacokinetics of intravenous heroin in subjects who are addicted to narcotics. Rentsch KM; Kullak-Ublick GA; Reichel C; Meier PJ; Fattinger K Clin Pharmacol Ther; 2001 Sep; 70(3):237-46. PubMed ID: 11557911 [TBL] [Abstract][Full Text] [Related]
34. Long-term effects of heroin-assisted treatment in Germany. Verthein U; Bonorden-Kleij K; Degkwitz P; Dilg C; Köhler WK; Passie T; Soyka M; Tanger S; Vogel M; Haasen C Addiction; 2008 Jun; 103(6):960-6; discussion 967-8. PubMed ID: 18422829 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341 [TBL] [Abstract][Full Text] [Related]
36. Heroin-assisted treatment in the Netherlands: History, findings, and international context. Blanken P; van den Brink W; Hendriks VM; Huijsman IA; Klous MG; Rook EJ; Wakelin JS; Barendrecht C; Beijnen JH; van Ree JM Eur Neuropsychopharmacol; 2010 Apr; 20 Suppl 2():S105-58. PubMed ID: 20362236 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of oral slow release morphine for maintenance treatment in heroin addicts: a 6-month open noncomparative study. Vasilev GN; Alexieva DZ; Pavlova RZ Eur Addict Res; 2006; 12(2):53-60. PubMed ID: 16543739 [TBL] [Abstract][Full Text] [Related]
38. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Rehm J; Gschwend P; Steffen T; Gutzwiller F; Dobler-Mikola A; Uchtenhagen A Lancet; 2001 Oct; 358(9291):1417-23. PubMed ID: 11705488 [TBL] [Abstract][Full Text] [Related]
39. Feasibility of double-blind clinical trials with oral diacetylmorphine: a randomized controlled phase II study in an inpatient setting. Colom Farran J; Casas M; Pérez de Los Cobos J; Del Río M; Roncero C; Castells X; Valero S; Eiroa-Orosa FJ; Batlle F; Trujols J Eur Addict Res; 2012; 18(6):279-87. PubMed ID: 22854605 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Girardin F; Rentsch KM; Schwab MA; Maggiorini M; Pauli-Magnus C; Kullak-Ublick GA; Meier PJ; Fattinger K Clin Pharmacol Ther; 2003 Oct; 74(4):341-52. PubMed ID: 14534521 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]